| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 1373487 | Bioorganic & Medicinal Chemistry Letters | 2007 | 4 Pages |
Abstract
A novel series of cyclic benzamidines was synthesized and shown to exhibit NR2B-subtype selective NMDA antagonist activity. Compound 29 is orally active in a carrageenan-induced rat hyperalgesia model of pain.
Graphical abstractA novel series of cyclic benzamidines was synthesized and shown to exhibit NR2B-subtype selective NMDA antagonist activity. Compound 29 is orally active in a carrageenan-induced rat hyperalgesia model of pain.Figure optionsDownload full-size imageDownload as PowerPoint slide
Related Topics
Physical Sciences and Engineering
Chemistry
Organic Chemistry
Authors
Kevin T. Nguyen, Christopher F. Claiborne, John A. McCauley, Brian E. Libby, David A. Claremon, Rodney A. Bednar, Scott D. Mosser, Stanley L. Gaul, Thomas M. Connolly, Cindra L. Condra, Bohumil Bednar, Gary L. Stump, Joseph J. Lynch, Kenneth S. Koblan,